亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Disentangling estimands and the intention‐to‐treat principle

随机对照试验 意向治疗分析 人口 医学 模棱两可 金标准(测试) 计算机科学 外科 环境卫生 内科学 程序设计语言
作者
Ann-Kristin Leuchs,Andreas Brandt,Jörg Zinserling,Norbert Benda
出处
期刊:Pharmaceutical Statistics [Wiley]
卷期号:16 (1): 12-19 被引量:22
标识
DOI:10.1002/pst.1791
摘要

Randomized controlled trials (RCTs) aim at providing reliable estimates of treatment benefit. Missing data and nonadherence to treatment are distinct problems that can substantially impede this task. In practice, the fact that the handling of missing data due to nonadherence affects the question that is addressed is often ignored. Estimands allow precisely predefining the question of interest. Estimands are definitions of that which is being estimated with regard to population, endpoint, and handling of postrandomization events (eg, nonadherence). Depending on the situation, different estimands are of relevance. Therefore, it is important that the intention‐to‐treat (ITT) principle, which is considered the gold standard for analyzing RCTs, does not restrict an RCT's primary objective to only one of several relevant estimands. Although much ambiguity is involved around what is considered to constitute the ITT principle, many associate ITT with completely following up all patients and including all data of all randomized patients as allocated into the analysis. This would restrict primary objectives to estimating the effect of treatment policy and is certainly not warranted in all situations. To maintain the advantage of having the clear recommendation to follow the ITT principle while allowing for various relevant estimands as primary objective, we argue that the appropriate way forward is to define ITT as including all randomized patients into the analysis set and each patient is to be allocated to his or her randomized treatment. This definition comprises the actual intent of ITT and can be fully implemented also in settings where complete follow‐up is impossible.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
共享精神应助难过的大山采纳,获得10
2秒前
5秒前
吴大王发布了新的文献求助10
9秒前
willlee完成签到 ,获得积分10
43秒前
55秒前
长乐发布了新的文献求助30
1分钟前
我是老大应助长乐采纳,获得30
1分钟前
大模型应助yyy2025采纳,获得10
1分钟前
1分钟前
长乐发布了新的文献求助30
1分钟前
2分钟前
2分钟前
yyy2025发布了新的文献求助10
2分钟前
2分钟前
2分钟前
2分钟前
希望天下0贩的0应助康康XY采纳,获得10
2分钟前
难过的大山完成签到,获得积分20
2分钟前
九霄完成签到 ,获得积分10
3分钟前
难过的大山关注了科研通微信公众号
3分钟前
扯不开的封口膜完成签到,获得积分10
3分钟前
3分钟前
Beto发布了新的文献求助30
3分钟前
充电宝应助Beto采纳,获得30
3分钟前
Orange发布了新的文献求助20
3分钟前
yzy发布了新的文献求助10
4分钟前
CFD应助yzy采纳,获得10
4分钟前
4分钟前
黑球发布了新的文献求助10
4分钟前
诸葛小哥哥完成签到 ,获得积分0
4分钟前
天天完成签到 ,获得积分10
5分钟前
5分钟前
Bin_Liu发布了新的文献求助10
5分钟前
a36380382完成签到,获得积分10
6分钟前
suxiaosi完成签到 ,获得积分10
6分钟前
TIDUS完成签到,获得积分10
6分钟前
jackone完成签到,获得积分10
6分钟前
6分钟前
TIDUS完成签到,获得积分10
6分钟前
华仔应助科研通管家采纳,获得10
6分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
Treatment of refractory idiopathic overactive bladder with incobotulinumtoxinA and vibe delivery system (XAVIER): pilot study 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6947178
求助须知:如何正确求助?哪些是违规求助? 8632027
关于积分的说明 18307354
捐赠科研通 6384929
什么是DOI,文献DOI怎么找? 3080372
关于科研通互助平台的介绍 2122914
邀请新用户注册赠送积分活动 2057258